Aim The win ratio can incorporate different types of outcomes and enhance statistical power,
making it a useful method for analysing composite outcomes in cardiovascular trials. The …

Aims Patients surviving an acute myocardial infarction (AMI) are at risk of developing
symptomatic heart failure (HF) or premature death. We hypothesized that …

Aims We aimed to investigate whether sacubitril–valsartan could further improve the
prognosis, cardiac function, and left ventricular (LV) remodelling in patients following acute …

Purpose: To systematically assess the efficacy and safety of sacubitril/valsartan (SV) by
comparison with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor …

Background In patients with symptomatic heart failure, sacubitril–valsartan has been found
to reduce the risk of hospitalization and death from cardiovascular causes more effectively …

Methods The design, baseline characteristics, and primary results of this institutional review
board–approved trial are published. 1, 2 In brief, PARADISE-MI was a double-blind, active …

Some randomized controlled trials have compared the effectiveness and safety outcomes
between early initiation of Sacubitril/Valsartan and angiotensin‐converting enzyme …

BACKGROUND: The VALIANT trial compared the efficacy and safety of captopril, valsartan,
and their combination in patients with left ventricular systolic dysfunction, heart failure, or …

To evaluate the effects and safety of sacubitril/valsartan in patients with acute myocardial
infarction (AMI), a total of four databases, including PubMed, Cochrane Library, Embase and …

Background: infarction (AMI) can be reduced by the use of sacubitril/valsartan. However, the
therapeutic effects of sacubitril/valsartan in clinical settings are inconsistent. In this paper …